The mining syringe of the brand “Wegovy” is sold in the Pharmacy Purchase in Mitte. The slimming “Wegovy” syringe has been available in Germany for a year.
Jens Kalaene | Photo alliance | Getty images
Novo Nordisk On Tuesday, he said that he will offer his medication as far as we weight Wegovy through remote providers Hims & His HealthRO and LIFEMD to extend access to successful treatment now that it is no longer in the short term in the United States
Hims & Hers’ shares climbed 18% on Tuesday, while Novo Nordisk shares increased by 3%.
The manufacturer of Danish drugs rushes to capture more patients now that many composition pharmacies are legally limited to make cheaper and not approved versions of Wegovy, with rare exceptions. Patients flocked to the composed versions while Wegovy was shortened due to demand for demand.
“We estimated that it was really important to work hard to establish a collaboration with TV companies so that there could be access to Wegovy while the aggravation ends,” said Dave Moore, executive vice-president of American operations in Novo Nordisk, in CNBC.
“We are really delighted with the level of interest to access the Wegovy brand and start catching people out of aggravated medicine,” he said.
Moore has added that new partnerships make the experience “transparent” for patients because it allows them to directly access Wegovy of their remote charters, which “makes them very easy” for them to have the medication ships directly to their homes.
Patients will be able to access the new Direct Consumption Direct Consumption of Novo Nordisk, directly through remote lining suppliers.
This pharmacy offers Wegovy for $ 499 in cash per month – approximately half of its usual monthly price – for patients without insurance coverage for weekly injection.
The price of each Télésanté company can be higher because it probably includes additional services, a spokesperson for Novo Nordisk told CNBC.
Novo Nordisk Table of one year stocks
Hims & Hers said that it would start to offer all Wegovy dose sizes as well as access to 24/7 care, nutritional advice and continuous clinical support this week, from $ 599 per month to cash admissible patients with a prescription.
The drug will cost Hims and HIS customers more, as it has additional access to Care, the company CEO, Andrew Dudum, in CNBC in an interview. He said he thought that company partnership with Novo Nordisk would serve as a case study for how patients have access and get prices for “Great Medicine” and other forms of treatment.
RO opted for the lower price, announcing Tuesday that it will offer access to all doses of Wegovy for $ 499 per month. The company provides 24/7 messages, individual coaching, educational content and more thanks to its monthly subscription called the Body program, which does not include the cost of drugs.
“The addition of treatments approved by the NOVO Nordisk FDA at the best available cash price will help more national patients to obtain the obesity care they need to achieve their objectives, in particular those without insurance coverage,” said RO CEO, Zach Reitano, in a press release.
Earlier this month, Hims & Hers announced that patients could access Eli Lilly Zepbounde’s weight loss drugs and Diabetes Diabetes Mounjaro, as well as generic injection liraglutide, via its platform. But unlike the collaboration of the company with Novo Nordisk, Lilly published a statement specifying that she has “no affiliation” with Hims & Hers.
Hims & Hers began to prescribe composed semaglutide, the active ingredient of the NOVO Nordisk Ozempic and Wegovy diabetes medication in May 2024. The company had to access personalized doses if it is clinically applicable, said Dudum.
“This was one of the first things we shared with Novo is that we will always fight in the name of what consumers we believe have the right to obtain,” said Dudum. “The regulations are very clear.”
During the shortages known as Food and Drug Administration, pharmacists can legally make versions made up of brand medicines. They can also be produced on a case -by -case basis when it is medically necessary for a patient, as when he cannot swallow a pill or is allergic to a specific ingredient in a brand medication.
But drug manufacturers and certain health experts have pushed the practice, largely because the FDA does not approve of compound medicines.
Composition pharmacies larger and regulated by the federal government which make copies of semaglutide in bulk without prescription are faced with a legal deadline of May 22 to stop the marketing and the sale of these versions. Smaller and state -related composition pharmacies that make semaglutide copycats for individual prescriptions have had a deadline of April 22.
“The spirit of this is that we remain faithful to the rules,” said Moore. “It’s the best way for us to serve patients.”
– Brandon Gomez and Angelica from CNBC contributed to this report.